Explore the categories so you can find more about your search.

Categorie > Clinical Trials / Drug Trials

Followup Of Patients With Interstitial Cystitis Responsive To Treatment With Intravesical Bacillus Calmette Guerin Or Placebo

Categorie : Clinical Trials / Drug Trials
UroToday.com - The Interstitial Cystitis Clinical Trials Group (ICCTG) recently reported the results of a randomized, double-blind, placebo controlled clinical trial of intravesical bacillus Calmette-Guerin (BCG). After 34 weeks of follow-up, there was no statistically significant difference betwee ...

read more UroToday.com - The Interstitial Cystitis Clinical Trials Group (ICCTG) recently reported the results of a randomized, double-blind, placebo controlled clinical trial of intravesical bacillus Calmette-Guerin (BCG). After 34 weeks of follow-up, there was no statistically significant difference betwee read more Wed Mar 2008 Wed Mar 2008

Comparison Of Outcomes Of Vasectomy Reversal

Categorie : Clinical Trials / Drug Trials
UroToday.com - This retrospective study compared postoperative semen analysis parameters and patency rates of vasovasostomy performed in the convoluted versus straight portion of the vas deferens. This study was undertaken to assess whether or not the perceived increased technical difficulty that m ...

read more UroToday.com - This retrospective study compared postoperative semen analysis parameters and patency rates of vasovasostomy performed in the convoluted versus straight portion of the vas deferens. This study was undertaken to assess whether or not the perceived increased technical difficulty that m read more Wed Mar 2008 Wed Mar 2008

Breakthroughs In Cancer Research At American Association For Cancer Research 2008 Annual Meeting

Categorie : Clinical Trials / Drug Trials
What:The AACR Annual Meeting features the latest cutting-edge findings in laboratory, translational and clinical cancer research. This year's meeting focuses on new and promising therapeutic approaches, as well as strides being made in diagnosing and preventing cancer.To help you take the best advan ...

read more What:The AACR Annual Meeting features the latest cutting-edge findings in laboratory, translational and clinical cancer research. This year's meeting focuses on new and promising therapeutic approaches, as well as strides being made in diagnosing and preventing cancer.To help you take the best advan read more Wed Mar 2008 Wed Mar 2008

Phase I/II Studies Of IMC-A12 In Pediatric Cancer Patients Commence Enrollment

Categorie : Clinical Trials / Drug Trials
ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, announced that the initial stage of a series of Phase I/II clinical trials of IMC-A12, its anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibod ...

read more ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, announced that the initial stage of a series of Phase I/II clinical trials of IMC-A12, its anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibod read more Wed Mar 2008 Wed Mar 2008

Participants Sought For Study Of Prolotherapy For Tennis Elbow At UPMC Shadyside

Categorie : Clinical Trials / Drug Trials
The Center for Integrative Medicine (CIM) at the University of Pittsburgh Medical Center (UPMC) is seeking participants for a study to evaluate the benefits of prolotherapy for tennis elbow. Prolotherapy is a non-surgical treatment used to stimulate repair of damaged ligaments and tendons. It uses a ...

read more The Center for Integrative Medicine (CIM) at the University of Pittsburgh Medical Center (UPMC) is seeking participants for a study to evaluate the benefits of prolotherapy for tennis elbow. Prolotherapy is a non-surgical treatment used to stimulate repair of damaged ligaments and tendons. It uses a read more Wed Mar 2008 Wed Mar 2008

Cerimon To Conduct A Proof Of Concept Study For Basiliximab For Noninfectious Uveitis, A Potentially Sight-Threatening Inflammation Of The Eye

Categorie : Clinical Trials / Drug Trials
Cerimon Pharmaceuticals announced it has entered into an agreement with Novartis Pharma AG to conduct a proof of concept study for Simulect(R) (basiliximab) for the treatment of noninfectious uveitis, an autoimmune inflammation of the eye's internal structures. Uveitis can cause severe visual impai ...

read more Cerimon Pharmaceuticals announced it has entered into an agreement with Novartis Pharma AG to conduct a proof of concept study for Simulect(R) (basiliximab) for the treatment of noninfectious uveitis, an autoimmune inflammation of the eye's internal structures. Uveitis can cause severe visual impai read more Wed Mar 2008 Wed Mar 2008

GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection For More Than Six Years

Categorie : Clinical Trials / Drug Trials
New data demonstrate that GlaxoSmithKline's (NYSE: GSK) cervical cancer candidate vaccine, CERVARIX(R) provides significant protection for women against the four most common cancer- causing human papillomavirus types for nearly six and a half years, the longest duration of protection reported to dat ...

read more New data demonstrate that GlaxoSmithKline's (NYSE: GSK) cervical cancer candidate vaccine, CERVARIX(R) provides significant protection for women against the four most common cancer- causing human papillomavirus types for nearly six and a half years, the longest duration of protection reported to dat read more Wed Mar 2008 Wed Mar 2008

NovaBay Pharmaceuticals Commences Phase I Human Clinical Trial For The Prevention Of Catheter Associated Urinary Tract Infections

Categorie : Clinical Trials / Drug Trials
NovaBay Pharmaceuticals, Inc. (AMEX & TSX: NBY, http://www.novabaypharma.com) announced that it had completed dosing of the first cohort of volunteers in a multi-cohort Phase I safety study of a bladder and catheter lavage solution of NVC-422, NovaBay's lead Aganocide compound. This clinical program ...

read more NovaBay Pharmaceuticals, Inc. (AMEX & TSX: NBY, http://www.novabaypharma.com) announced that it had completed dosing of the first cohort of volunteers in a multi-cohort Phase I safety study of a bladder and catheter lavage solution of NVC-422, NovaBay's lead Aganocide compound. This clinical program read more Wed Mar 2008 Wed Mar 2008

Alcon Presents Clinical Trial Data On Anecortave Acetate For Glaucoma

Categorie : Clinical Trials / Drug Trials
Alcon, Inc. (NYSE: ACL) released the primary efficacy and safety results of the second controlled proof of concept clinical study of anecortave acetate administered as an anterior juxtascleral depot in the sub-Tenon's space to reduce intraocular pressure in patients with open-angle glaucoma. These i ...

read more Alcon, Inc. (NYSE: ACL) released the primary efficacy and safety results of the second controlled proof of concept clinical study of anecortave acetate administered as an anterior juxtascleral depot in the sub-Tenon's space to reduce intraocular pressure in patients with open-angle glaucoma. These i read more Wed Mar 2008 Wed Mar 2008

GSK Statement On MHRA Investigation

Categorie : Clinical Trials / Drug Trials
GlaxoSmithKline (GSK) notes the conclusions announced by the Medicines and Healthcare products Regulatory Agency (MHRA) regarding its investigation into disclosure of paediatric trial data for the anti-depressant medicine Seroxat (paroxetine)."The safe use of our medicines is paramount to everyone w ...

read more GlaxoSmithKline (GSK) notes the conclusions announced by the Medicines and Healthcare products Regulatory Agency (MHRA) regarding its investigation into disclosure of paediatric trial data for the anti-depressant medicine Seroxat (paroxetine). read more Wed Mar 2008 Wed Mar 2008

Alseres Pharmaceuticals Presents Inosine And Dopamine Transporter (DAT) Blocker Preclinical Data At The ASENT Conference

Categorie : Clinical Trials / Drug Trials
Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) announced that data from preclinical studies of the Company's nerve repair candidate, Inosine, and DAT Blocker product candidates from its neurodegeneration program were presented at the ASENT conference, March 6-8, 2008 in Arlington, VA. ...

read more Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) announced that data from preclinical studies of the Company's nerve repair candidate, Inosine, and DAT Blocker product candidates from its neurodegeneration program were presented at the ASENT conference, March 6-8, 2008 in Arlington, VA. read more Wed Mar 2008 Wed Mar 2008

Nventa Enrolls And Initiates Dosing Of Final Cohort In HspE7 Phase 1 Cervical Dysplasia Trial

Categorie : Clinical Trials / Drug Trials
Nventa Biopharmaceuticals Corporation (TSX: NVN) announced that the Company has completed enrollment and initiated dosing of the fourth and final cohort of patients in its Phase 1 dose escalation trial. This study examines the safety of its lead candidate, new HspE7 (HspE7 + Poly-ICLC, a toll-like ...

read more Nventa Biopharmaceuticals Corporation (TSX: NVN) announced that the Company has completed enrollment and initiated dosing of the fourth and final cohort of patients in its Phase 1 dose escalation trial. This study examines the safety of its lead candidate, new HspE7 (HspE7 + Poly-ICLC, a toll-like read more Wed Mar 2008 Wed Mar 2008

GARDASIL Will Spare Thousands A Diagnosis Of Cell Abnormality That May Lead To More Tests And Possibly Surgery

Categorie : Clinical Trials / Drug Trials
A significant drop in abnormal Pap test results happened after girls and women were given a vaccine to prevent cervical cancer, according to a researcher at the University of Alabama at Birmingham (UAB).The findings show the vaccine, named GARDASIL, appears to prevent the development of cell changes ...

read more A significant drop in abnormal Pap test results happened after girls and women were given a vaccine to prevent cervical cancer, according to a researcher at the University of Alabama at Birmingham (UAB).The findings show the vaccine, named GARDASIL, appears to prevent the development of cell changes read more Wed Mar 2008 Wed Mar 2008

Would Investigator Attendance At Review Board Reviews Be A Hindrance Or Help?

Categorie : Clinical Trials / Drug Trials
Inviting researchers to attend institutional review board sessions designed to approve these same investigators' requests to conduct research involving human subjects doesn't seem to affect the efficiency of the process one way or the other, a new study led by Johns Hopkins bioethicists suggests. ...

read more Inviting researchers to attend institutional review board sessions designed to approve these same investigators' requests to conduct research involving human subjects doesn't seem to affect the efficiency of the process one way or the other, a new study led by Johns Hopkins bioethicists suggests. read more Wed Mar 2008 Wed Mar 2008

Oramed Pharmaceuticals Successfully Completes Phase 1B Clinical Trials Of Oral Insulin Capsule

Categorie : Clinical Trials / Drug Trials
Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB http://www.oramed.com), a developer of oral delivery systems, has successfully completed Phase 1B clinical trials of its oral insulin capsule. The Phase 1B trial, which utilized healthy volunteers, was focused on finding the optimal dosage for the ...

read more Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB http://www.oramed.com), a developer of oral delivery systems, has successfully completed Phase 1B clinical trials of its oral insulin capsule. The Phase 1B trial, which utilized healthy volunteers, was focused on finding the optimal dosage for the read more Wed Mar 2008 Wed Mar 2008

The Effect Of Shock Wave Rate On The Outcome Of Shock Wave Lithotripsy: A Meta-Analysis

Categorie : Clinical Trials / Drug Trials
UroToday.com- In this manuscript, the authors reviewed 4 randomized trials of shock wave lithotripsy comparing slow shock wave delivery (i.e. 60 shock waves/ min) to rapid shock wave delivery (120 shocks/minute), comprising 589 patients treated on 4 different lithotriptors (2 with electrohydraulic a ...

read more UroToday.com- In this manuscript, the authors reviewed 4 randomized trials of shock wave lithotripsy comparing slow shock wave delivery (i.e. 60 shock waves/ min) to rapid shock wave delivery (120 shocks/minute), comprising 589 patients treated on 4 different lithotriptors (2 with electrohydraulic a read more Fri Feb 2008 Fri Feb 2008

Preliminary Phase II Results Of Abiraterone Acetate In Patients With Castration-resistant Metastatic Prostate Cancer

Categorie : Clinical Trials / Drug Trials
UroToday.com - Dr. Danila, spoke about abiraterone acetate (AA), an oral and irreversible inhibitor of CYP17 that decreases testosterone and DHT levels to undetectable. The study presented sought to determine the proportion of patients achieving a PSA decline of >50% and to assess toxicity. It was a ...

read more UroToday.com - Dr. Danila, spoke about abiraterone acetate (AA), an oral and irreversible inhibitor of CYP17 that decreases testosterone and DHT levels to undetectable. The study presented sought to determine the proportion of patients achieving a PSA decline of >50% and to assess toxicity. It was a read more Fri Feb 2008 Fri Feb 2008

Exploring New Technologies For Glaucoma Clinical Drug Trials

Categorie : Clinical Trials / Drug Trials
The National Eye Institute (NEI) and the Food and Drug Administration (FDA) sponsored a symposium to consider new disease-relevant outcome measures appropriate for evaluating glaucoma therapies.Currently, clinical drug trials for glaucoma therapies rely on standard perimetric criteria - i.e., a visi ...

read more The National Eye Institute (NEI) and the Food and Drug Administration (FDA) sponsored a symposium to consider new disease-relevant outcome measures appropriate for evaluating glaucoma therapies.Currently, clinical drug trials for glaucoma therapies rely on standard perimetric criteria - i.e., a visi read more Fri Feb 2008 Fri Feb 2008

Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety And Efficacy Data With Picoplatin In Metastatic Prostate Cancer Patients

Categorie : Clinical Trials / Drug Trials
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, announced that it is presenting safety and efficacy data in prostate cancer patients from its Phase 1 study of picoplatin, the Company's lead product candidate, at the 2008 Genitourinary (GU) Cancers Sympo ...

read more Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, announced that it is presenting safety and efficacy data in prostate cancer patients from its Phase 1 study of picoplatin, the Company's lead product candidate, at the 2008 Genitourinary (GU) Cancers Sympo read more Fri Feb 2008 Fri Feb 2008

European Science Foundation 's EMRC Strengthens Training Course On Clinical Trials Management

Categorie : Clinical Trials / Drug Trials
Around 170 doctors, nurses and medical researchers from Europe and North America were given important insights into how to run successful clinical trials across national boundaries at a two-day training course in Croydon, UK.The course, sponsored by the European Science Foundation as part of its Pan ...

read more Around 170 doctors, nurses and medical researchers from Europe and North America were given important insights into how to run successful clinical trials across national boundaries at a two-day training course in Croydon, UK.The course, sponsored by the European Science Foundation as part of its Pan read more Fri Feb 2008 Fri Feb 2008

<<< previous | 1 | 2 | 3 | 4 | 5 next >>>



     


Custom Search